Combinatorial inhibition of MEK/ERK and γ-secretase increases efficacy in melanoma, papillary thyroid cancer, and CRC (Krepler et al., 2016, Yamashita et al., 2013, Schmidt et al., 2018). The gene discussed is EPHB2; the disease is colorectal carcinoma.